Catalent Biologics to Present at INTERPHEX
SOMERSET, N.J. – March 26, 2019 — Catalent Pharma Solutions (Booth 1145), the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, today announced that two of its manufacturing experts will present at the INTERPHEX Conference and Exhibition, taking place at the Javits Center, New York City, on April 2-4, 2019.
On Tuesday, April 2 at 10:30 a.m., at the CMO/CDMO Pavilion Theatre Booth 1153, Jo Anne Jacobs, Fellow, Manufacturing Technology Specialist, Catalent Biologics, will present “Critical Steps for a Successful Drug Product Tech Transfer”. In her presentation, Ms. Jacobs will discuss the essential elements needed to achieve a successful manufacturing process transfer, including planning, consistency, and communication, a discussion that is relevant for all drug products, regardless of where they are in their lifecycle.
Catalent will also participate in two panel discussions at the conference on the Innovation Stage on Wednesday, April 3. The first, taking place at 11 a.m., is titled “Meeting Bioprocessing Manufacturing Capacity Demands” and will feature Steve Perry, Senior Director, Manufacturing Sciences, Catalent Biologics. The second, taking place at 1:30 p.m., is entitled “Aseptic Processing” and will feature Ms. Jacobs.
Ms. Jacobs has been in the pharmaceutical industry for over 20 years and has extensive experience in the manufacturing of parenteral products, and additional experience with dry blending, wet granulation, fluid-bed drying and tablet coating. At Catalent, she works closely with multi-disciplinary teams to ensure the successful technical transfer of both clinical and commercial products. Ms. Jacobs is also a registered pharmacist with hospital and community pharmacy experience. She has been active in several industry organizations over the course of her career, including the BioPhorum Operations Group (BPOG), Parenteral Drug Association (PDA), American Association of Pharmaceutical Scientists (AAPS), International Society for Pharmaceutical Engineering (ISPE) and the South Carolina Pharmaceutical Association.
Mr. Perry has over 25 years of experience in biopharmaceutical manufacturing, and has held senior roles at Johnson and Johnson, ImClone Systems (now part of Eli Lilly), Cytovance Biologics and Trek Diagnostics. He joined Catalent in 2010 and is responsible for drug substance tech transfer, scale-up, and has oversight of manufacturing campaigns. Mr. Perry earned his bachelor’s degree from Purdue University, West Lafayette, Indiana, and his master’s degree from the Massachusetts Institute of Technology, both in chemical engineering. He also has an MBA from Northwestern University’s Kellogg School of Management.
To arrange a meeting with any of the attending Catalent executives at the event, contact Ed Dutton at NEPR – edward@nepr.agency.
Media Contacts:
Chris Halling
+44 (0)7580 041073
chris.halling@catalent.com
Richard Kerns
+44 (0)161 728 5880
richard@nepr.eu
About Catalent
Catalent is the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products. With 85 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable clinical and commercial product supply. Catalent employs over 11,000 people, including over 1,800 scientists, at more than 30 facilities across five continents, and in fiscal 2018 generated approximately $2.5 billion in annual revenue. Catalent is headquartered in Somerset, New Jersey. For more information, visit www.catalent.com.